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Nerve growth factor (NGF) induces degranulation of rat peritoneal mast cells (RPMC) in a dose-dependent 
manner, providing direct evidence for its action on non-neuronal tissues. Activation of RPMC by NGF 
depends on lysophosphatidylserine and extracellular calcium. NGF-mediated RPMC degranulation is not 
coupled to a transient increase in intracellular free calcium ([Ca*+],). It is suggested that NGF has a unique 
mode of action independent of [Caz+], and presumably also without involving protein kinase C activation 
as indicated by the effects of phorbol esters and NGF on antigen-evoked [Ca”], rise. 
Nerve growth factor 12-O-Tetradecanoylphorbol I3-acetate (Rat peritoneal mast cell, Rat leukemia cell line) 
Degranulation 
1. INTRODUCTION 
Nerve growth factor (NGF) is a well character- 
ized neuronotrophic polypeptide which is essential 
for the normal development and function of sym- 
pathetic and sensory neurones [l]. This polypep- 
tide is synthesized in target tissues innervated by 
sympathetic and sensory nerves [2,3]. NGF in- 
itiates its characteristic effects by interacting with 
specific surface receptors on the plasma membrane 
of neuronal target cells [4]. Furthermore, NGF has 
been shown to elicit biological effects on non- 
neuronal tissues, such as a rapid shape change of 
blood platelets [5], an increase in the number of 
mast cells in neonatal rats [6] and degranulation of 
mast cells [7]. The recent finding that biologically 
active NGF stimulates an increase in vascular 
permeability in the rat skin [8] and the detection of 
high (nanomolar) concentrations of NGF im- 
munoreactivity in joint effusions of experimentally 
induced arthritis and in pleural and peritoneal ex- 
udates in rats (Weskamp and Otten, unpublished) 
suggest that NGF is involved in inflammatory 
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Ca2+ 
responses [9]. In this study we show that NGF is an 
effective secretagogue for mast cells, an effect 
blocked by specific monoclonal antibodies against 
NGF. Unlike antigenic stimulation, NGF does not 
elevate [Ca’+]i as measured by quin-2 fluorescence. 
2. MATERIALS AND METHODS 
2.1. Preparation of NGF and its antibody 
2.5 S NGF was isolated from the submaxillary 
glands of adult male mice according to Suda et al. 
[lo]. 2.5 S NGF was further purified by gel filtra- 
tion on a Biogel P 30 column (2.6 by 90 cm) 
equilibrated with 50 mM Tris-HCl, pH 7.4. The 
purified NGF migrated as a single band in SDS- 
polyacrylamide gel electrophoresis. Biological ac- 
tivity was monitored by following the dose- 
dependent neurite outgrowth of PC 12 rat 
pheochromocytoma cells [ 111. Monoclonal an- 
tibodies to 2.5 S NGF were generated by conven- 
tional procedures [ 121. Briefly, Sprague-Dawley 
rats were immunized with 2.5 S mouse NGF ac- 
cording to the procedure of Sttihli et al. [13]. 
Spleen cells were fused with FO myeloma cells [ 141 
with polyethylene glycol and plated at about lo5 
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cells per well in a selection medium comprised of 
Dulbecco’s modified Eagle’s medium (hypoxan- 
thine, aminopterine, thymidine and 10% fetal calf 
serum). Hybridomas producing anti-NGF an- 
tibodies were screened by a solid-phase im- 
munoassay and cloned twice by limiting dilution 
[15]. Clone 23 C4 producing an antibody of the 
IgG2a subclass which inhibits neurite outgrowth 
from sensory neurones and PC 12 cells was used in 
our experiments. 
2.2. Preparation of cells and degranulation 
measurements 
Male Sprague-Dawley rats (250-300 g) were 
decapitated after anaesthetizing with diethyl ether. 
50 ml Tyrode buffer (137.0 mM NaCl, 2.7 mM 
KCl, 0.4 mM NaHzPOd, 10 mM Hepes, 5 mM 
glucose, 1.8 mM CaC12, 1.0 mM MgC12, pH 7.4) 
were injected into the peritoneal cavity of each rat. 
Peritoneal cavity was then opened by a midline in- 
cision; the fluid collected contained about 3% 
mast cells. Separation of mast cells was carried out 
by density gradient centrifugation. The gradient 
was composed of a lower layer of 1 ml Tyrode con- 
taining 0.26 g/ml bovine serum albumin (BSA) 
and an upper layer containing 0.20 g/ml BSA onto 
which a 5 ml suspension of peritoneal cells was 
placed. Mast cells were pelleted by centrifugation 
at 900 x g for 10 min. The purity of mast cells 
recovered from the bottom of the tube was 80%. 
The cells were washed twice with 10 ml Tyrode 
buffer before being divided into aliquots for the 
release experiments. RBL-2H3 cells were grown in 
Eagle’s minimal essential medium (with Earle’s 
salts) supplemented with 20% fetal calf serum, 
1 mM glutamine, 200 IU penicillin/ml and 200 pg 
streptomycin/ml (supplied by Gibco). Cells were 
plated in 250 ml Nunc tissue culture T flasks, at 
37”C, in a humid, 5% CO2 atmosphere incubator. 
Cells for the experiments were taken in the early 
stationary growth phase, 48 h after transfer, and 
removed from the flask by means of a rubber 
policeman. Assay of serotonin release: 10’ cells 
were incubated for 24 h at 37°C in 10 ml 
RPMI-1640 medium containing 1.2-2.5 x 
10m6 mol [3H]serotonin (5 mCi/ml, Amersham) 
and plated into 96-well flat-bottom microtiter 
plates (Nunclon; lo5 cells in 100,J medium per 
well). The cells were passively sensitized by incuba- 
tion with ascitic fluid containing dinitrophenyl 
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(DNP)-specific monoclonal IgE antibodies [ 161, 
150 ~1 of a 1 : 50 dilution per well for 1 h at 4°C. 
The supernatants were removed and the cells 
washed twice with medium to remove unbound 
IgE. The cells were challenged to release 
[3H]serotonin by adding either 0.2-1.0 ng of the 
antigen (DNP)s-BSA (a covalent conjugate of an 
average of 8 DNP groups attached to BSA) or 
10-9-10-7 M NGF in 150 ~1 medium per well, and 
plates incubated for 30 min at 37°C. 100~1 
samples were removed from each well into a 
toluene-Triton scintillation liquid for determina- 
tion of [3H]serotonin release. The total radiola- 
beled serotonin incorporated into cells was 
estimated by dissolving the cells in 100~1 of 1 N 
NaOH and counting the whole sample. Release 
was expressed as a percentage of the total 
[3H]serotonin incorporated. The degranulation 
process was monitored by either the fluorimetric 
histamine method of Shore [17] or by a modifica- 
tion of the procedure for measuring [3H]serotonin 
release described by Taurog et al. [ 181. Briefly, ali- 
quots of 0.9 ml of a peritoneal cell suspension (lo5 
cell/ml) were equilibrated at 37°C in Tyrode solu- 
tion. NGF or compound 48/80 were added in a 
volume of 0.1 ml and incubation was carried out at 
37°C for 10 min. The reaction was stopped with 
2 ml of ice-cold Ca’+-free Tyrode solution. The 
cells were sedimented by centrifugation at 1000 x 
g for 5 min. Aliquots from the supernatants were 
reacted with 0.4 ml of 1 N NaOH and 0.1 ml of o- 
phthalaldehyde (10 mg/ml in methanol) for 4 min 
at room temperature, and then 0.2 ml of 3 N HCl 
was added. The fluorescence emitted by the 
samples at 450 nm after excitation at 360 nm was 
monitored on a Perkin-Elmer fluorimeter. 
2.3. Measurement of [Cd’/i 
Cells were maintained as described. Attached 
cells were collected 48 h after passage by repeated 
pipetting and suspended in Tyrode buffer contain- 
ing 0.1% BSA, pH 7.4. The cells (1 x 106/ml) were 
incubated with a monoclonal, DNP-specific, IgE 
antibody for 1 h at 37°C. After 3 washes with 
Tyrode buffer, aliquots of cells (each 5 x 10’ 
cells/ml) were subsequently incubated with 
100 PM quin-2 acetoxymethyl ester (quin-2) 
(AME, Ciba-Geigy, Basel) for 15 min at 37°C. 
Aliquots of the cell suspension (2 x lo6 cells) were 
then centrifuged and the supernatants discarded. 
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The cell pellets were resuspended to a final volume 
of 2 ml each and transferred to l-cm optical 
pathway quartz cuvettes, continuously stirred by 
an inserted electrical stirrer. Fluorescence changes 
were monitored on a Perkin-Elmer spec- 
trofluorimeter (excitation 339 nm, emission 
492 nm). Hydrolysis of quin-2-AME to quin-2 and 
its uptake into the cells were examined by follow- 
ing the shift in emission maximum from 435 to 
492 nm. Agent-induced changes in [Ca”]i were 
quantified as detailed by Rink et al. [19] with 
modifications [20]. Cellular leakage was checked 
by addition of 0.5 mM MnClz to the samples. In- 
tracellular free Ca2+ concentrations were 
calculated using the following formula: 
[Ca2+]i = kn(F - Fmi,)/(Fm,, - F) 
where kD (115 nM) represents the dissociation con- 
stant of quin-2, F the fluorescence measured in in- 
tact cells, F,,,,, the fluorescence in lysed cells at 
2 mM Ca2+ in the medium and Fmin at 10 nM 
Ca2+, pH 8.3. 
3. RESULTS AND DISCUSSION 
As shown in fig.1 NGF causes dose-dependent 
histamine secretion from rat peritoneal mast cells 
(RPMC). The effect of NGF on degranulation is 
dependent on the presence of lysophosphatidyl- 
80 1 
70 
60 
I 
Concentratm M 
Fig.1. Histamine release from rat peritoneal mast cells. 
Dose dependency of compound 48/80 ( n ) and NGF (0). 
Each point represents the mean of 5 independent 
experiments performed in duplicates with SE < 10%. 
Spontaneous histamine release was <i’% and was 
subtracted from total release. 
serine (1ysoPS) and extracellular Ca2+ (table 1). 
NGF-mediated degranulation was compared with 
the prototypical histamine releasing compound 
48/80, low-M, polyamine (fig.1). In the presence 
of 1ysoPS (1 PM) a significant 5% net release (P < 
0.05) is achieved at 10m9 M NGF while the half- 
maximal effect was evident at 5 x lo-* M, 
reaching saturation (60-70% histamine release) at 
lo-’ M NGF. Histamine release was completed 
within 5 min and was not due to cell damage as 
monitored by the presence of lactate dehydrogen- 
ase in the medium. The specificity of the NGF- 
mediated degranulation was examined by mono- 
clonal anti-NGF antibodies. Preincubation of 
RPMC with monoclonal anti-NGF antibodies 
(1 0e6 M) markedly reduced NGF-mediated secre- 
tion by 65% (table 1). 
These results prompted us to investigate in detail 
the mechanisms underlying NGF-mediated secre- 
tion. The following question was addressed: Does 
NGF (~19.3) produce its effect via stimulation of 
specific membrane receptors or by a more non- 
specific action common to basic proteins [21]? The 
Table 1 
Modulation of NGF-induced degranulation 
Treatment % degranulation 
Rat mast Rat baso- 
cells philic leuke- 
mia cells 
(RBL-2H3) 
Unstimulated cells + lysoPS 5-l 4-6 
- 1ysoPS (W6 M) 7 6 
+ monoclonal anti-NGF 
antibodies (10m6 M) 7 4 
+ EDTA (1O-3 M) 7 6 
NGF-stimulated cells + 
IysoPS 71 65 
- lysoPS 12 36 
+ monoclonal anti-NGF 
antibodies ( 10e6 M) 29 26 
+ EDTA (1O-3 M) 7 6 
+ Mg’+ (1 mM; Ca2+-free) 5 6 
NGF-induced degranulation of mast cells and RBL-2H3 
cells. Effect of lysophosphatidylserine (lysoPS), 
monoclonal anti-NGF antibodies, the Ca2+ chelator 
EDTA and Mg’+ 
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fact that NGF-induced histamine secretion is 
dependent on IysoPS and extracellular Ca’+ (in 
contrast to basic proteins) indicates that NGF 
elicits its effects by a more specific mechanism, 
presumably via specific receptors, as demonstrated 
by the inhibition of NGF-dependent degranulation 
by anti-NGF antibodies. To study the cellular 
mechanisms of exocytosis evoked by NGF- 
receptor activation we used the rat basophilic 
leukemia cell line RBL-2H3, increasingly used as a 
model system for examining the cellular 
mechanisms involved in stimulus-secretion cou- 
pling [22]. One of the generally accepted early 
events in neurotransmitter and hormone-receptor 
activation is the stimulation of inositol phospho- 
lipid breakdown and subsequent mobilization of 
[Ca2+]i [23]. Therefore, changes in [Ca*“]t were 
monitored by using the fluorecent Ca2+ indicator 
quin-2 [19] following treatment of RBL-2H3 cells 
with NGF. Surprisingly, NGF in concentrations up 
to lo-’ M did not affect the resting intracellular 
Ca2+ concentration (fig.2) although it caused a 
massive degranulation. In contrast, exocytosis of 
passively sensitized RBL-2H3 cells induced by an- 
tigen (DNP)s-BSA led to a rapid and transient in- 
crease in [Ca’+]i, ranging from 90 + 5 nM (mean 
f SE, n = 8) in resting conditions up to an average 
peak value of 403 & 21 nM (n = 8) (fig.2). There- 
fore, we conclude that the mode of NGF action 
differs from the immunological triggering path- 
way. On the other hand, the characteristics of the 
NGF response are very similar to mast cell de- 
granulation induced by 12-~-tetradecanoylphor- 
bol 13-acetate (TPA) [24]. Both agents induce ex- 
ocytosis without affecting [Ca2+]i. Since protein 
kinase C is the receptor for phorbol esters, the 
hypothesis that NGF action is mediated via this 
b) 
multifunctional enzyme was tested [25]. This 
assumption was examined by studying the regula- 
tory effects of either TPA or NGF on the antigen- 
coupled JCa2+]i signals (fig.3). Upon stimulation 
with antigen (figs 2a and 3aI) a rapid increase in 
the internal Ca2+ concentration of RBL-2H3, from 
an initial value of 90 f 5 to 403 f 21 nM (average 
of 8 different experiments), was observed. Maxi- 
mal increase in [Ca2+]i was reached within 1 min 
and decreased 2 min later, returning to basal levels 
within 30 min after stimulation. Addition of TPA 
(1.5-75 nM) failed to trigger any change in the in- 
ternal Ca2+ concentration (not shown). However, 
TPA at 75 nM completely blocked the antigen-in- 
duced Ca” signal (fig.3bI). When added im- 
mediately after the antigen, TPA rapidly reversed 
the Ca2+ signal (fig.3aII). In contrast, NGF (up to 
low7 M) had no effect on the antigen-induced 
[Ca2+]i signal regardless of whether it was added 
before or after antigen stimulation (fig.3bII,aIII). 
These data suggest a unique mode of action of 
NGF operating distal from protein kinase C and 
[Ca2+]i. Such a model, however, does not exclude 
synergism between phorbol esters and NGF in in- 
ducing degranulation. Indeed, it has been shown 
that phorbol esters synergize with NGF to induce 
neurite outgrowth in PC 12 rat pheochromocy- 
toma cells [26]. 
Our findings suggest hat in peripheral targets 
there might be close communications between in- 
nervating sensory neurones and non-neuronal cells 
which are mediated by NGF. On the one hand, 
NGF regulates the development and function of 
substance P-containing sensory neurones [9,27,28] 
whereas on the other it elicits non-cytotoxic release 
of mediator substances, including histamine from 
peritoneal mast cells. The liberated histamine 
Fmax 
- _ 0NP8-EEA NGF 
- 
Fmm 
1 ml” 
Fig.2. Fluorescence changes induced by antigen and NGF in RBL-2H3 cells loaded with quin-2, reflecting [Ca”],. 
Response of the cells to (a) 1 ng/mI antigen (DNP)&SA, (b) 10s7 M NGF. These traces show the results of a typical 
experiment. Similar results were obtained in 8 similar experiments. 
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T bl bl1 
Fig.3. (a) Effect of TPA and NGF on fluorescence changes induced by antigen on RBL-2H3 cells loaded with quin-2. 
Effect of TPA (75 nM) (all) and NGF (IO-’ M) (alll) on Ca2+ signal when added during the rise of the Ca2+ signal 
induced by (DNP)s-BSA (I ng/ml) (al). (b) Effect of TPA (75 nM) (bl) and NGF (IO-’ M) (bll) on the Ca2+ signal 
when preincubated for 2 min before the addition of (DNP)s-BSA (1 ng/ml). 
directly activates terminals of certain primary sen- 
sory neurones to release substance P, a potent mast 
cell-depleting agent [29]. A local feedback cycle 
controlled by NGF might be of importance in 
pathophysiological conditions, such as neurogenic 
inflammation. However it remains to be seen 
whether the observations reported here are ap- 
plicable to other types of mast cells [30]. 
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